These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 21724705

  • 21. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
    Ogrendik M.
    Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
    [Abstract] [Full Text] [Related]

  • 22. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
    O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, Fernandez A, Blakely K, Wees S, Stoner J, Hadley S, Felt J, Palmer W, Waytz P, Churchill M, Klassen L, Moore G.
    Arthritis Rheum; 2002 May; 46(5):1164-70. PubMed ID: 12115219
    [Abstract] [Full Text] [Related]

  • 23. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis.
    Yellin M, Paliienko I, Balanescu A, Ter-Vartanian S, Tseluyko V, Xu LA, Tao X, Cardarelli PM, Leblanc H, Nichol G, Ancuta C, Chirieac R, Luo A.
    Arthritis Rheum; 2012 Jun; 64(6):1730-9. PubMed ID: 22147649
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study.
    Gibofsky A, Rodrigues J, Fiechtner J, Berger M, Pan S.
    Clin Ther; 2007 Jun; 29(6):1071-85. PubMed ID: 17692722
    [Abstract] [Full Text] [Related]

  • 25. MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study.
    Vergunst CE, Gerlag DM, von Moltke L, Karol M, Wyant T, Chi X, Matzkin E, Leach T, Tak PP.
    Arthritis Rheum; 2009 Dec; 60(12):3572-81. PubMed ID: 19950299
    [Abstract] [Full Text] [Related]

  • 26. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group.
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [Abstract] [Full Text] [Related]

  • 27. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
    Nuki G, Bresnihan B, Bear MB, McCabe D, European Group Of Clinical Investigators.
    Arthritis Rheum; 2002 Nov; 46(11):2838-46. PubMed ID: 12428223
    [Abstract] [Full Text] [Related]

  • 28. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
    Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M.
    Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
    [Abstract] [Full Text] [Related]

  • 29. Randomized controlled trial comparing 2 different starting doses of methotrexate in rheumatoid arthritis.
    Dhir V, Singla M, Gupta N, Goyal P, Sagar V, Sharma A, Khanna S, Singh S.
    Clin Ther; 2014 Jul 01; 36(7):1005-15. PubMed ID: 24976447
    [Abstract] [Full Text] [Related]

  • 30. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.
    Choy E, McKenna F, Vencovsky J, Valente R, Goel N, Vanlunen B, Davies O, Stahl HD, Alten R.
    Rheumatology (Oxford); 2012 Jul 01; 51(7):1226-34. PubMed ID: 22344576
    [Abstract] [Full Text] [Related]

  • 31. Subcutaneous administration of polymerized-type I collagen for the treatment of patients with rheumatoid arthritis. An open-label pilot trial.
    Furuzawa-Carballeda J, Cabral AR, Zapata-Zuñiga M, Alcocer-Varela J.
    J Rheumatol; 2003 Feb 01; 30(2):256-9. PubMed ID: 12563677
    [Abstract] [Full Text] [Related]

  • 32. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, Burge DJ.
    Arthritis Rheum; 2004 Feb 01; 50(2):353-63. PubMed ID: 14872476
    [Abstract] [Full Text] [Related]

  • 33. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
    Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P.
    J Rheumatol; 2000 Apr 01; 27(4):841-50. PubMed ID: 10782805
    [Abstract] [Full Text] [Related]

  • 34. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.
    Fleischmann RM, Cohen SB, Moreland LW, Schiff M, Mease PJ, Smith DB, Keenan G, Kremer JM, iRAMT Study Group.
    Curr Med Res Opin; 2005 Aug 01; 21(8):1181-90. PubMed ID: 16083527
    [Abstract] [Full Text] [Related]

  • 35. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
    Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, Hanrahan PS, Kraishi MM, Patel A, Sun G, Bear MB, 990145 Study Group.
    Ann Rheum Dis; 2004 Sep 01; 63(9):1062-8. PubMed ID: 15082469
    [Abstract] [Full Text] [Related]

  • 36. A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis.
    Furst DE, Fleischmann R, Kopp E, Schiff M, Edwards C, Solinger A, Macri M, 990136 Study Group.
    J Rheumatol; 2005 Dec 01; 32(12):2303-10. PubMed ID: 16331754
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.
    Lü LJ, Teng JL, Bao CD, Han XH, Sun LY, Xu JH, Li XF, Wu HX.
    Chin Med J (Engl); 2008 Apr 05; 121(7):615-9. PubMed ID: 18466681
    [Abstract] [Full Text] [Related]

  • 39. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone.
    O'Dell JR, Elliott JR, Mallek JA, Mikuls TR, Weaver CA, Glickstein S, Blakely KM, Hausch R, Leff RD.
    Arthritis Rheum; 2006 Feb 05; 54(2):621-7. PubMed ID: 16447240
    [Abstract] [Full Text] [Related]

  • 40. Traditional herbal medicines (Kampo) for patients with rheumatoid arthritis receiving concomitant methotrexate: a preliminary study.
    Kogure T, Tatsumi T, Sato H, Oku Y, Kishi D, Ito T.
    Altern Ther Health Med; 2010 Feb 05; 16(1):46-51. PubMed ID: 20085177
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.